Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 4

Case Presentation 1: PIK3CA Mutation With ESR1 Mutations

,

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.

  1. How does this truncal vs acquired distinction impact treatment strategies for ESR1 mutation-positive disease?
    • What criteria are used to classify ESR1 mutations as truncal vs acquired?